PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Colesevelam hydrochloride - Lipid modification

PAD Profile : Colesevelam hydrochloride - Lipid modification

Keywords :
high cholesterol, raised cholesterol, lipid lowering, hyperlipidaemia, FH, familial hypercholesterolaemia, lipid modifying drugs
Brand Names Include :
Cholestagel

Traffic Light Status

Status 1 of 1.

Status :
Blue
Important
Formulations :
  • Tablets
Important Information :
Hypercholesterolaemia. Primary care prescribing on specialist team recommendation.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
01 March 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The PCN recommends, as per NICE CG71 (updated July 2016), that patients with Familial Hyperchosterolaemia (FH) with intolerance or contraindications to statins or ezetimibe, should be offered a referral to a specialist with expertise in FH for consideration for treatment with either a bile acid sequestrant (resin), nicotinic acid or a fibrate to reduce their LDL-C concentration. For those patients, bile acid sequestrants should be considered BLUE (without an information sheet) on the traffic light system Specialists to initiate treatment or make a recommendation for the primary care prescriber to initiate treatment.

See below for policy statement and further information

Associated BNF Codes

02. Cardiovascular System
02.12.00. Lipid-regulating drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More